drugset
Drugs / Lu-PSMA
last change Apr 2026 re-read 3 minutes ago

Lu-PSMA

also known as 177Lu-PSMA-617 · 177Lutetium -PSMA 617 also referred to as 177Lu-PSMA · [(177)Lu]Lu-PSMA-617
Developed for
castration-resistant prostate carcinoma
Investigated by
Astellas Pharma Inc · Australian and New Zealand Urogenital and Prostate Cancer Trials Group · Endocyte · National Health and Medical Research Council, Clinical Trials Centre · Prostate Cancer Research Alliance

Trials 1

today NCT04419402 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04419402 Aug 2020 → Apr 2024 overdue castration-resistant prostate carcinoma Australian and New Zealand Urogenital and Prostate Cancer Trials Group Active not recruiting Met primary

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Lu-PSMA ClinicalTrials.gov intervention name — accepted as the source's own label NCT04419402 ↗
Known as 177Lu-PSMA-617 “Background Lutetium 177 (177Lu) prostate-specific membrane antigen (PSMA)-617 SPECT/CT has demonstrated promise as a response biomarker for 177Lu-PSMA-617 therapy.” PMID 42048586 ↗ Apr 2026
Known as 177Lutetium -PSMA 617 also referred to as 177Lu-PSMA “177Lutetium -PSMA 617 also referred to as 177Lu-PSMA” NCT04419402 ↗
Known as [(177)Lu]Lu-PSMA-617 “Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p):...” PMID 39956124 ↗ Feb 2025
Route Intravenous “intravenous 7·5 GBq [177Lu]Lu-PSMA-617” PMID 39956124 ↗ Feb 2025